Edition:
United Kingdom

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

13.90USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$13.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
38,033
52-wk High
$18.00
52-wk Low
$6.85

Chart for

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: 2.57
Market Cap(Mil.): $107.52
Shares Outstanding(Mil.): 8.37
Dividend: --
Yield (%): --

Financials

  EIGR.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -5.69 -- --
ROI: -116.96 2.00 14.38
ROE: -143.95 3.49 16.08

BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

* EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 May 2018

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

21 Mar 2018

BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11

* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

16 Jan 2018

UPDATE 2-Eiger to abandon blood pressure drug after trial failure

* Shares slump about 46 pct in morning trading (Adds details on company's pipeline, CEO's and analyst comment, background on PAH; updates share movement)

16 Jan 2018

Eiger BioPharma abandons blood pressure drug after failed study

Jan 16 Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

16 Jan 2018

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

16 Jan 2018

Earnings vs. Estimates